KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) EBITDA (2016 - 2026)

Eli Lilly filings provide 18 years of EBITDA readings, the most recent being $9.5 billion for Q1 2026.

  • On a quarterly basis, EBITDA rose 80.35% to $9.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $33.4 billion, a 77.64% increase, with the full-year FY2025 number at $29.2 billion, up 80.56% from a year prior.
  • EBITDA hit $9.5 billion in Q1 2026 for Eli Lilly, up from $8.9 billion in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $9.5 billion in Q1 2026 to a low of $1.6 billion in Q1 2023.
  • Median EBITDA over the past 5 years was $3.4 billion (2023), compared with a mean of $4.3 billion.
  • Biggest five-year swings in EBITDA: crashed 37.78% in 2023 and later soared 101.07% in 2025.
  • Eli Lilly's EBITDA stood at $2.1 billion in 2022, then surged by 44.94% to $3.0 billion in 2023, then soared by 77.35% to $5.3 billion in 2024, then surged by 66.8% to $8.9 billion in 2025, then increased by 6.69% to $9.5 billion in 2026.
  • The last three reported values for EBITDA were $9.5 billion (Q1 2026), $8.9 billion (Q4 2025), and $8.0 billion (Q3 2025) per Business Quant data.